AC Immune (ACIU) Competitors $2.28 +0.13 (+6.05%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.26 -0.01 (-0.66%) As of 09/5/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. IOVA, TSHA, NAGE, AVBP, DAWN, DNTH, VALN, DNA, TNGX, and GYREShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Iovance Biotherapeutics (IOVA), Taysha Gene Therapies (TSHA), Niagen Bioscience (NAGE), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Valneva (VALN), Ginkgo Bioworks (DNA), Tango Therapeutics (TNGX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors Iovance Biotherapeutics Taysha Gene Therapies Niagen Bioscience ArriVent BioPharma Day One Biopharmaceuticals Dianthus Therapeutics Valneva Ginkgo Bioworks Tango Therapeutics Gyre Therapeutics AC Immune (NASDAQ:ACIU) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Do analysts rate ACIU or IOVA? AC Immune presently has a consensus price target of $12.00, suggesting a potential upside of 426.32%. Iovance Biotherapeutics has a consensus price target of $11.90, suggesting a potential upside of 377.91%. Given AC Immune's stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Iovance Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36 Do institutionals & insiders hold more shares of ACIU or IOVA? 51.4% of AC Immune shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, ACIU or IOVA? AC Immune has higher earnings, but lower revenue than Iovance Biotherapeutics. AC Immune is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$31.02M7.38-$57.83M-$0.58-3.93Iovance Biotherapeutics$241.53M3.73-$372.18M-$1.23-2.02 Which has more volatility and risk, ACIU or IOVA? AC Immune has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Does the media prefer ACIU or IOVA? In the previous week, AC Immune and AC Immune both had 5 articles in the media. AC Immune's average media sentiment score of 1.57 beat Iovance Biotherapeutics' score of 1.43 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACIU or IOVA more profitable? Iovance Biotherapeutics has a net margin of -161.44% compared to AC Immune's net margin of -174.94%. AC Immune's return on equity of -49.35% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AC Immune-174.94% -49.35% -23.16% Iovance Biotherapeutics -161.44%-52.87%-41.31% SummaryAC Immune beats Iovance Biotherapeutics on 9 of the 15 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$215.88M$3.13B$5.81B$9.92BDividend YieldN/A2.28%6.71%4.52%P/E Ratio-3.9321.1076.0226.12Price / Sales7.38283.48477.0086.71Price / CashN/A44.9736.9659.04Price / Book1.779.8711.456.09Net Income-$57.83M-$53.42M$3.29B$266.51M7 Day Performance11.76%2.93%1.22%0.45%1 Month Performance5.07%9.85%7.89%4.58%1 Year Performance-23.75%15.74%62.81%26.06% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune1.9493 of 5 stars$2.28+6.0%$12.00+426.3%-26.7%$215.88M$31.02M-3.93140News CoveragePositive NewsHigh Trading VolumeIOVAIovance Biotherapeutics4.1761 of 5 stars$2.23flat$11.90+433.6%-76.2%$806.93M$164.07M-1.81500Positive NewsTSHATaysha Gene Therapies2.3771 of 5 stars$2.92+3.2%$8.29+183.8%+59.2%$796.56M$8.33M-8.59180News CoverageNAGENiagen Bioscience2.4201 of 5 stars$9.90+0.8%$13.42+35.6%N/A$789.55M$99.60M47.15120AVBPArriVent BioPharma2.1 of 5 stars$19.12-0.5%$39.14+104.7%-24.1%$775.68MN/A-4.7640Positive NewsDAWNDay One Biopharmaceuticals2.5629 of 5 stars$7.51-1.1%$25.29+236.7%-47.9%$769.26M$131.16M-7.9160News CoveragePositive NewsDNTHDianthus Therapeutics2.2029 of 5 stars$23.57-5.0%$54.00+129.1%-5.3%$758.68M$6.24M-7.2580News CoveragePositive NewsVALNValneva2.2821 of 5 stars$8.85+0.1%$15.33+73.3%+22.3%$753.08M$183.52M-9.03700Analyst UpgradeShort Interest ↑Gap DownDNAGinkgo Bioworks1.5734 of 5 stars$12.71+4.4%$9.50-25.3%+80.9%$750.06M$227.04M-2.17640News CoverageGap DownTNGXTango Therapeutics2.3721 of 5 stars$6.71-1.6%$10.50+56.5%-40.6%$746.56M$42.07M-5.0590News CoverageGYREGyre Therapeutics1.5409 of 5 stars$7.74-6.5%$18.00+132.6%-34.9%$745.46M$105.76M774.7740 Related Companies and Tools Related Companies Iovance Biotherapeutics Competitors Taysha Gene Therapies Competitors Niagen Bioscience Competitors ArriVent BioPharma Competitors Day One Biopharmaceuticals Competitors Dianthus Therapeutics Competitors Valneva Competitors Ginkgo Bioworks Competitors Tango Therapeutics Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
